Results 221 to 230 of about 106,008 (282)
NLRP3 Inflammasome and Polycystic Ovary Syndrome (PCOS): A Novel Profile in Adipose Tissue. [PDF]
Alenezi SA +3 more
europepmc +1 more source
ABSTRACT Atherosclerosis, a chronic inflammatory–metabolic disorder, remains a leading cause of cardiovascular morbidity worldwide. This review explores the emerging paradigm of nanomedicine‐based targeting of macrophage immunometabolic reprogramming as a potentially transformative strategy for atherosclerosis treatment.
Zhenyu Liu, Wenfan Yang, Na Wang, Ya Wu
wiley +1 more source
TGFβ1 attenuates microglial IL1β release through inhibition of NLRP3 inflammasome priming. [PDF]
Kalischer C +8 more
europepmc +1 more source
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu +4 more
wiley +1 more source
NLRP3 inflammasome-mediated platelet hyperreactivity in sickle cell mice is targetable by BTK inhibition. [PDF]
Vogel S +9 more
europepmc +1 more source
Nigericin‐Triggered Phosphodynamics in Inflammasome Formation and Pyroptosis
ABSTRACT Innate immune signaling relies heavily on phosphorylation cascades to mount effective immune responses. Although traditional innate immune signaling cascades following TLR4 stimulation have been investigated through a temporally quantitative phosphoproteomic lens, far fewer studies have applied these methods to distinct signaling following the
Vanya Bhushan +5 more
wiley +1 more source
The NLRP3 inflammasome as a key pathway in the affective and chronic fatigue symptoms of Long COVID. [PDF]
Zhang Y +3 more
europepmc +1 more source
Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang +5 more
wiley +1 more source

